Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 3 9Phase NA 7Phase EARLY_PHASE1 4Phase 4 4Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Adenocarcinoma 1

Interventions

Paclitaxel 9Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Cisplatin 8Carboplatin 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Radiotherapy, Intensity-Modulated 6Nivolumab 6Leucovorin 6Filgrastim 6Drug Therapy 6Doxorubicin 6Radiotherapy 5Oxaliplatin 5Fluorouracil 5Docetaxel 5Bevacizumab 5pembrolizumab 4gallium 68 PSMA-11 4Taxes 4Sirolimus 4Rituximab 4Pemetrexed 4Melphalan 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Metformin × Clear all
NCT02065687 2021-09-30

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

GOG Foundation

Phase 2/3 Unknown
469 enrolled 16 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡